Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer

被引:0
|
作者
Nathalie Harder
Maria Athelogou
Harald Hessel
Nicolas Brieu
Mehmet Yigitsoy
Johannes Zimmermann
Martin Baatz
Alexander Buchner
Christian G. Stief
Thomas Kirchner
Gerd Binnig
Günter Schmidt
Ralf Huss
机构
[1] Definiens AG,Department of Urology
[2] Institute for Pathology,undefined
[3] Ludwig-Maximilians-University,undefined
[4] Ludwig-Maximilians-University,undefined
[5] Carl Zeiss Meditec AG,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tissue Phenomics is the discipline of mining tissue images to identify patterns that are related to clinical outcome providing potential prognostic and predictive value. This involves the discovery process from assay development, image analysis, and data mining to the final interpretation and validation of the findings. Importantly, this process is not linear but allows backward steps and optimization loops over multiple sub-processes. We provide a detailed description of the Tissue Phenomics methodology while exemplifying each step on the application of prostate cancer recurrence prediction. In particular, we automatically identified tissue-based biomarkers having significant prognostic value for low- and intermediate-risk prostate cancer patients (Gleason scores 6–7b) after radical prostatectomy. We found that promising phenes were related to CD8(+) and CD68(+) cells in the microenvironment of cancerous glands in combination with the local micro-vascularization. Recurrence prediction based on the selected phenes yielded accuracies up to 83% thereby clearly outperforming prediction based on the Gleason score. Moreover, we compared different machine learning algorithms to combine the most relevant phenes resulting in increased accuracies of 88% for tumor progression prediction. These findings will be of potential use for future prognostic tests for prostate cancer patients and provide a proof-of-principle of the Tissue Phenomics approach.
引用
收藏
相关论文
共 50 条
  • [1] Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer
    Harder, Nathalie
    Athelogou, Maria
    Hessel, Harald
    Brieu, Nicolas
    Yigitsoy, Mehmet
    Zimmermann, Johannes
    Baatz, Martin
    Buchner, Alexander
    Stief, Christian G.
    Kirchner, Thomas
    Binnig, Gerd
    Schmidt, Guenter
    Huss, Ralf
    SCIENTIFIC REPORTS, 2018, 8
  • [2] Management of low- and intermediate-risk prostate cancer
    Henk van der Poel
    Laurence Klotz
    Christian G. Stief
    World Journal of Urology, 2015, 33 : 905 - 906
  • [3] Management of low- and intermediate-risk prostate cancer
    van der Poel, Henk
    Klotz, Laurence
    Stief, Christian G.
    WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 905 - 906
  • [4] Active surveillance in low- and intermediate-risk prostate cancer
    Cerbone, Linda
    Regine, Giovanni
    Calabro, Fabio
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 582 - 583
  • [5] Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
    Kishan, Amar U.
    King, Christopher R.
    SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (03) : 268 - 278
  • [6] PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice
    Ricevuto, Enrico
    Morgani, Celeste
    Seri, Fabrizia
    Bruera, Gemma
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 567 - 568
  • [7] Longitudinal regret after treatment for low- and intermediate-risk prostate cancer
    Hurwitz, Lauren M.
    Cullen, Jennifer
    Kim, Daniel J.
    Elsamanoudi, Sally
    Hudak, Jane
    Colston, Maryellen
    Travis, Judith
    Kuo, Huai-Ching
    Rice, Kevin R.
    Porter, Christopher R.
    Rosner, Inger L.
    CANCER, 2017, 123 (21) : 4252 - 4258
  • [8] Pure Hypofractionated Radiotherapy for the Treatment of Low- to Intermediate-Risk Prostate Cancer
    Stephens, R.
    Gopaul, D.
    Panjwani, D.
    Lock, M.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S732 - S732
  • [9] Current focal therapies for the treatment of low- and intermediate-risk prostate cancer
    Malorgio, Antonio
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 592 - 594
  • [10] Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
    Kunogi, Hiroaki
    Wakumoto, Yoshiaki
    Kawamoto, Terufumi
    Oshima, Masaki
    Horie, Shigeo
    Sasai, Keisuke
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (06) : 554 - 561